Skip to main content
Premium Trial:

Request an Annual Quote

Single Technologies Raises $1.6M to Develop NGS Platform

NEW YORK – Single Technologies today announced it has raised SEK15 million ($1.6 million) to support further development of its next-generation sequencing platform.

Stockholm-based Single Technologies raised the funding via a convertible bond issue. JovB Holding, a Swedish investment firm, acted as the lead investor. The company said it will use the proceeds to support development of its products.

Called Theta, Single Technologies' platform relies on automated fluidics and single molecule-sensitive imaging to improve sequencing throughput. By enabling users to scale their sequencing projects, the company believes its technology will find use in population genomics and single-cell sequencing, among other applications.

CEO Johan Strömqvist said in a statement that Theta will enable "faster and more cost-efficient sequencing" in different sample types. He said the company intends to raise more funds before summer.

Single Technologies was founded in 2014 based on research into single-molecule imaging and biotechnology at the Royal Institute of Technology (KTH) in Stockholm, as well as on R&D in fiber optical grating done at Proximion, a fiber optics company based in Kista, Sweden.

The Scan

RNA Editing in Octopuses Seems to Help Acclimation to Shifts in Water Temperature

A paper in Cell reports that octopuses use RNA editing to help them adjust to different water temperatures.

Topical Compound to Block EGFR Inhibitors May Ease Skin Toxicities, Study Finds

A topical treatment described in Science Translational Medicine may limit skin toxicities seen with EGFR inhibitor therapy.

Dozen Genetic Loci Linked to Preeclampsia Risk in New GWAS

An analysis of genome-wide association study data in JAMA Cardiology finds genetic loci linked to preeclampsia that have ties to blood pressure.

Cancer Survival Linked to Mutational Burden in Pan-Cancer Analysis

A pan-cancer paper appearing in JCO Precision Oncology suggests tumor mutation patterns provide clues for predicting cancer survival that are independent of other prognostic factors.